Table 1.
Clinical characteristics of the patients in the training and test cohorts.
| Training Cohort (n = 179) | Test Cohort (n = 77) | |||||
|---|---|---|---|---|---|---|
| Negative for LN Metastasis | Positive for LN Metastasis | P Value | Negative for LN Metastasis | Positive for LN Metastasis | P Value | |
| No. Patients | 89 | 90 | 38 | 39 | ||
| Age (y) | 53.69 ± 8.35 | 50.32 ± 7.24 | 0.004 | 54.37 ± 7.69 | 48.31 ± 7.34 | 0.001 |
| CA125 (miu/ml) | 0.682 | 0.615 | ||||
| ≧35 miu/ml | 87 (97.8%) | 86 (95.6%) | 36 (94.7%) | 38 (97.4%) | ||
| <35 miu/ml | 2 (2.2%) | 4 (4.4%) | 2 (5.3%) | 1 (2.6%) | ||
| CA199 (miu/ml) | 0.072 | 0.481 | ||||
| ≧30.9 miu/ml | 7 (7.9%) | 16 (17.8%) | 5 (13.2%) | 3 (7.7%) | ||
| <30.9 miu/ml | 82 (92.1%) | 74 (82.2%) | 33 (86.8%) | 36 (92.3%) | ||
| Ascites | 0.074 | 0.335 | ||||
| Present | 73 (82%) | 82 (91.1%) | 30 (78.9%) | 34 (87.2%) | ||
| Absent | 16 (18%) | 8 (8.9%) | 8 (21.1%) | 5 (12.8%) | ||
| CT_T_stage | 0.000 | 0.000 | ||||
| I–II | 34 (38.2%) | 7 (7.8%) | 13 (34.2%) | 0 (0%) | ||
| III–IV | 55 (61.8%) | 83 (92.2%) | 25 (65.8%) | 39 (100%) | ||
| Laterality (%) | 0.069 | 0.014 | ||||
| Unilateral | 34 (38.2%) | 23 (25.6%) | 19 (50%) | 9 (23.1%) | ||
| Bilateral | 55 (61.8%) | 67 (74.4%) | 19 (50%) | 30 (76.9%) | ||
| CT_tumor size | 85.23 ± 35.89 | 83.76 ± 28.71 | 0.762 | 86.78 ± 38.29 | 78.54 ± 27.59 | 0.281 |
| CT_LN_report | 0.000 | 0.000 | ||||
| Negative | 78 (87.6%) | 45 (50%) | 36 (94.7%) | 20 (51.3%) | ||
| Positive | 11 (12.4%) | 45 (50%) | 2 (5.3%) | 19 (48.7%) | ||
| Radscore | −0.424 ± 0.875 | 0.441 ± 0.905 | 0.000 | −0.349 ± 1.529 | 0.514 ± 0.972 | 0.004 |
CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; CT_T_stage, CT_reported tumor stage; CT_tumor size, CT_reported tumor size; CT_LN_report, CT_reported lymph node status.